Ospedale S G Moscati — Clinical Trial Site

23 Registered trials

18 Currently recruiting

Organisation

Ospedale S G Moscati

Location

Statte, Italy

Identifier

ORG-100041772

Address

Via Per Martina Franca, 74010, Italy

Departments

Department of Oncology
Infectious Diseases
Medical oncology
Oncologia
Oncologia - Ospedale S. G. Moscati - Statte (TA)
Oncologia Medica
Oncology
Pneumologia
Pneumology
Pulmonary Medicine
SC di Oncologia Medica
SC Oncologia Medica
Struttura Complessa Oncologia Medica
U.O. Oncologia Medica
U.O.C. Oncologia Medica
UOC EMATOLOGIA
UOC Pneumologia

Clinical trials at this site (23)

Search interface

Study Evaluating Tarlatamab After Chemoradiotherapy in Limited‑Stage Small‑Cell Lung Cancer (DeLLphi-306) Recruiting

2023-506235-15-00 Limited-Stage Small-Cell Lung Cancer (LS SCLC) 5 2024-11-07
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants with Early Breast Cancer (EMBER-4) Recruiting

2022-501007-28-00 Breast Neoplasms 5 2023-04-18
A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting

2024-517337-41-00 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutat 5 2026-05-12
ROMANCE Recruiting

2025-521319-38-00 metastatic colorectal cancer 4 2026-03-11
A clinical study of MK-1084 and other treatments for lung cancer (MK-1084-007) Recruiting

2024-514500-14-00 Participants with KRAS G12C-Mutant, Advanced or Metasta 5 2025-12-15
A Study in TKI-naive Patients With Advanced ALK-Positive NSCLC ( ALKAZAR ) Recruiting

2024-517553-26-00 Advanced ALK-positive non-small cell lung cancer (NSCLC 5 2025-11-12
A study to investigate the effect of AZD6793 in participants with moderate to very severe chronic obstructive pulmonary disease Recruiting

2025-520473-40-00 Moderate to Very Severe Chronic Obstructive Pulmonary D 4 2025-09-29
CAPRI-3 Phase 3 clinical study to evaluate the use of continuing cetuximab treatment beyond first line progression in molecular selected met… Recruiting

2024-519322-20-00 metastatic colorectal cancer 5 2025-07-21
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Recurrent ovarian cancer 5 2025-01-09
A phase II randomized clinical study of the combination of avelumab plus cetuximab as rechallenge strategy in pre-treated RAS/BRAF wild type… Recruiting

2024-519481-44-00 colorectal metastatic cancer 4 2025-01-08
PHASE III STUDY WITH ATEZOLIZUMAB VERSUS PLACEBO IN MALIGNANT PLEURAL MESOTHELIOMA PATIENTS AFTER PLEURECTOMY/DECORTICATION Recruiting

2024-519286-21-00 MALIGNANT PLEURAL MESOTHELIOMA PATIENTS 5 2024-12-17
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 BRCA wild-type advanced ovarian, fallopian tube and pri 4 2024-12-09
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left … Recruiting

2023-509551-14-00 Unresectable left sided RAS/B-RAF wild-type metastatic 5 2024-06-12
Investigate the efficacy and safety of a bio-marker driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RA… Recruiting

2024-518534-81-00 metastatic colorectal cancer 4 2021-07-01
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced recta… Recruiting

2024-519007-10-00 Locally advanced stage II/III rectal cancer 10 2020-10-22
Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting

2023-510433-29-00 Favorable-intermediate-risk Acute Myeloid Leukemia 5 2020-09-24
Phase II randomized trial comparing atezolizumab versus atezolizumab plus bevacizumab as first-line treatment in PD-L1 high advanced non-sm… Recruiting

2024-517200-10-00 Advanced non-small-cell lung cancer 4 2020-01-31
The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended

2023-508968-30-00 Adult Philadelphia Chromosome-Positive Acute Lymphoblas 5 2021-09-08
Long-term Efficacy and Safety of Tozorakimab in Participants with Chronic Obstructive Pulmonary Disease with a History of Exacerbations. Ended

2022-501063-41-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2023-04-20
Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) Ended

2022-500363-12-00 SARS CoV-2 (COVID-19) 4 2022-08-24
Study to assess efficacy, safety, and tolerability of Tozorakimab in patients with symptomatic chronic obstructive pulmonary disease (COPD) … Ended

2023-503572-24-00 Chronic Obstructive Pulmonary Disease (COPD) 5 2022-03-02
European DisCoVeRy for Solidarity: An Adaptive Pandemic and Emerging Infection Platform Trial (SolidAct) Ended

2022-500385-99-00 SARS-CoV II infection (Coronavirus disease) 5 2021-06-03